"The technology behind Beat has really been developed over about ten years with a group of founders who have received this 50 million in NIH funding. And again, for people who don’t know, they don’t just hand out that money. So you have to be leaders in your field and our founders are."
- Michael Kranda, CEO Beat Biotherapeutics
Heart disease is the leading cause of death in the United States, with 400,000 to 700,000 new cases of heart failure every year in the U.S. alone. Fueling a revolution in the treatment of heart failure through a novel biological therapy, this company takes advantage of known cardiovascular processes to drive protein production and thus significantly improve cardiac performance. This differs from current commonplace treatment options that have proven insufficiently potent. A successful go-to-market strategy will lead to the implementation of a preventive and effective remedy for heart failure cases.
For more exclusive CEO interviews and information about the latest trends in healthcare technology, subscribe to our weekly newsletter.